Articles

Carotid stenting is a more complex and challenging procedure than coronaries or peripheral vessels. Carotid stenting experts have the following advice for hospitals and physicians that want to...

In a move that will likely have a significant impact on how many patients are treated for carotid artery disease, the U.S. Food and Drug Administration (FDA) in May cleared the use of a stent to...

In a move that will likely have a significant impact how many patients are treated for carotid artery disease, the U.S. Food and Drug Administration (FDA) has cleared the use of a stent to treat...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...

April 8, 2011 — A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with...

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of Cardiology (ACC) Scientific Session in New Orleans. The trial compared the...

April 6, 2011 – The second phase of a trial evaluating the world’s first drug-eluting bioresorbable vascular scaffold (BVS) showed positive one-year results. Data from the ABSORB Trial, which...

April 6, 2011 – A pooled analysis of the SPIRIT II, III, IV and COMPARE trials further reinforces the positive clinical performance of an everolimus eluting coronary stent system.

January 10, 2011 – European CE mark approval was announced today for the Abbott, Absorb drug-eluting bioresorbable coronary stent. It is the first bioresorbable stent to gain regulatory approval...